Waldemar F. Carlo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Waldemar F. Carlo has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Luz A. Padilla
Department of Epidemiology The University of Alabama at Birmingham Birmingham Alabama USA
6 shared publications James K. Kirklin
Kirklin Institute for Research in Surgical Outcomes The University of Alabama at Birmingham Birmingham Alabama USA
4 shared publicationsRobert J. Dabal
Heart Transplant Program Children’s of Alabama Birmingham AL USA
4 shared publicationsMeloneysa Hubbard
Children's of Alabama Heart Transplant Program Birmingham AL USA
3 shared publications- Adrien Lokangaka
Kinshasa School of Public Health
2 shared publications - Antoinette Tshefu
Affiliation Ecole de Santé Publique, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
2 shared publications
Latest Publications
- 8 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70418
Author Response to Dr. Imamura
- 8 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70418
Author Response to Dr. Imamura
- Open Access
- 23 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70374
Comparing Outcomes of Heartmate 3 and Heart Transplantation in Older Children With Dilated Cardiomyopathy—Can Transplantation be Delayed or Avoided?
Background: Children with end‐stage dilated cardiomyopathy (DCM) usually undergo heart transplantation or a short‐term bridge with a ventricular assist device. Heartmate 3 (HM3) may represent an appealing longer‐term option, though pediatric data are limited. We analyzed two clinical registries and hypothesized that adolescents with DCM treated with either HM3 or transplant would present similar survival. Methods: The Pedimacs and Pediatric Heart Transplant Society registries were queried for DCM patients ages 10–18 years treated with HM3 or transplant, between 2017 and 2022. Mortality and adverse events were reported. Results: Ninety HM3 and 306 transplant patients were reported within the respective registries. There was a higher proportion of Black patients in the HM3 cohort (40% vs. 30% in the transplant cohort, p = 0.03). Twelve‐ and 36‐month survival rates were both 94.4% for HM3 patients and were 99.3% and 95.6% for transplant patients. In the HM3 group, there were 66 transplants (median time of 2.8 months), 3 late explants for recovery, and 3 early deaths. Conditional 1‐year survival for HM3 and transplant was 100% and 96.3%, respectively, at 3 years. In the HM3 group, bleeding, stroke, and device malfunction rates were low at 0.1 events per patient per year. Conclusions: Adolescents with DCM treated with either HM3 or transplant had excellent 3‐year outcomes, though many HM3 pediatric patients are transplanted early after device placement. Safely supporting this group of patients for an extended duration with HM3 has implications for delaying/avoiding transplantation, longer‐term patient survival, and donor organ availability.
- 23 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70374
Open AccessComparing Outcomes of Heartmate 3 and Heart Transplantation in Older Children With Dilated Cardiomyopathy—Can Transplantation be Delayed or Avoided?
Background: Children with end‐stage dilated cardiomyopathy (DCM) usually undergo heart transplantation or a short‐term bridge with a ventricular assist device. Heartmate 3 (HM3) may represent an appealing longer‐term option, though pediatric data are limited. We analyzed two clinical registries and hypothesized that adolescents with DCM treated with either HM3 or transplant would present similar survival. Methods: The Pedimacs and Pediatric Heart Transplant Society registries were queried for DCM patients ages 10–18 years treated with HM3 or transplant, between 2017 and 2022. Mortality and adverse events were reported. Results: Ninety HM3 and 306 transplant patients were reported within the respective registries. There was a higher proportion of Black patients in the HM3 cohort (40% vs. 30% in the transplant cohort, p = 0.03). Twelve‐ and 36‐month survival rates were both 94.4% for HM3 patients and were 99.3% and 95.6% for transplant patients. In the HM3 group, there were 66 transplants (median time of 2.8 months), 3 late explants for recovery, and 3 early deaths. Conditional 1‐year survival for HM3 and transplant was 100% and 96.3%, respectively, at 3 years. In the HM3 group, bleeding, stroke, and device malfunction rates were low at 0.1 events per patient per year. Conclusions: Adolescents with DCM treated with either HM3 or transplant had excellent 3‐year outcomes, though many HM3 pediatric patients are transplanted early after device placement. Safely supporting this group of patients for an extended duration with HM3 has implications for delaying/avoiding transplantation, longer‐term patient survival, and donor organ availability.
- 12 January 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 173 (3) , 1362-1371
Non‐study post‐partum antibiotics use and risk of maternal and neonatal infection: A secondary analysis of the A‐ PLUS randomized controlled trial
Objective: The randomized trial of azithromycin to reduce maternal and neonatal sepsis (the A‐PLUS Trial) found substantial reduction in maternal sepsis among women receiving azithromycin and substantial non‐study antibiotic use. This secondary analysis explored the effect modification of non‐study antibiotics on azithromycin versus placebo on maternal and newborn infection among A‐PLUS participants. Methods: Women ≥28 weeks gestation in labor and planning a vaginal delivery at a study hospital in seven low‐ and middle‐income countries (Bangladesh, India [two sites], Pakistan, Guatemala, Kenya, Democratic Republic of Congo, and Zambia) were eligible for inclusion. Non‐study antibiotic use was collected prospectively. We estimated the interaction of non‐study antibiotics with azithromycin versus placebo on maternal and newborn sepsis. Results: A total of 29 287 participants were randomized (14 590 to azithromycin; 14 688 to placebo). Maternal infection was reduced among the azithromycin group compared to placebo among those who did not receive non‐study antibiotics, with estimated relative risk (RR) 0.58 (95% confidence interval [CI] 0.48, 0.70), and among those who received non‐study antibiotics, with RR 0.80 (95% CI 0.70, 0.91). Similar results were observed for maternal sepsis. Neonatal infection was not significantly reduced in any group. These results were similar when stratified by African and Asian region but not statistically significant. Conclusion: Our results suggest a benefit of azithromycin in reducing maternal infection or sepsis across all groups, with a larger reduction in risk among participants who had not received other antibiotics. Given the concerns of inappropriate use of antibiotics, further research is warranted to determine the most effective strategies of reducing risk of infection.
- 12 January 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 173 (3) , 1362-1371
Non‐study post‐partum antibiotics use and risk of maternal and neonatal infection: A secondary analysis of the A‐ PLUS randomized controlled trial
Objective: The randomized trial of azithromycin to reduce maternal and neonatal sepsis (the A‐PLUS Trial) found substantial reduction in maternal sepsis among women receiving azithromycin and substantial non‐study antibiotic use. This secondary analysis explored the effect modification of non‐study antibiotics on azithromycin versus placebo on maternal and newborn infection among A‐PLUS participants. Methods: Women ≥28 weeks gestation in labor and planning a vaginal delivery at a study hospital in seven low‐ and middle‐income countries (Bangladesh, India [two sites], Pakistan, Guatemala, Kenya, Democratic Republic of Congo, and Zambia) were eligible for inclusion. Non‐study antibiotic use was collected prospectively. We estimated the interaction of non‐study antibiotics with azithromycin versus placebo on maternal and newborn sepsis. Results: A total of 29 287 participants were randomized (14 590 to azithromycin; 14 688 to placebo). Maternal infection was reduced among the azithromycin group compared to placebo among those who did not receive non‐study antibiotics, with estimated relative risk (RR) 0.58 (95% confidence interval [CI] 0.48, 0.70), and among those who received non‐study antibiotics, with RR 0.80 (95% CI 0.70, 0.91). Similar results were observed for maternal sepsis. Neonatal infection was not significantly reduced in any group. These results were similar when stratified by African and Asian region but not statistically significant. Conclusion: Our results suggest a benefit of azithromycin in reducing maternal infection or sepsis across all groups, with a larger reduction in risk among participants who had not received other antibiotics. Given the concerns of inappropriate use of antibiotics, further research is warranted to determine the most effective strategies of reducing risk of infection.
- Open Access
- 9 August 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8)
A Single Center Study of Mortality and Associated Risk Factors After Transfer of Care From a Pediatric to an Adult Heart Transplant Center
Purpose: At many pediatric institutions, heart transplant recipients eventually transition to adult providers. Outcomes after this transfer of care are not well studied. Methods: We conducted a single center review of pediatric heart transplant patients who underwent transfer of care to the adjacent adult heart transplant center. Patient mortality and associated variables were analyzed. Results: Forty‐eight patients were transferred at a mean age of 19 ± 0.9 years, with 3.9 ± 2.7 years of follow‐up time after transfer. There were 14 (29.2%) patient deaths at a median time of 1.3 years after transfer. On survival analysis, Black race ( p < 0.001), public insurance ( p = 0.04), single parent household ( p = 0.057), treated rejection in the final year before transfer ( p < 0.001), and shorter interval between transplant and transfer of care ( p = 0.003) were all associated in a univariate fashion with mortality. On multivariable analysis, recent rejection (HR 6.29, 95% CI 1.6–25.1) and time between transplant and transfer of care (HR 0.75, 95% CI 0.6–1) were associated with an increased and decreased risk, respectively, of mortality. Conclusions: Our results reveal the extent of mortality after transfer of care to an adult institution and suggest possible associations between mortality and the following risk factors: race, socioeconomic characteristics, older age at transplant, and recently treated rejection.
- 9 August 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8)
Open AccessA Single Center Study of Mortality and Associated Risk Factors After Transfer of Care From a Pediatric to an Adult Heart Transplant Center
Purpose: At many pediatric institutions, heart transplant recipients eventually transition to adult providers. Outcomes after this transfer of care are not well studied. Methods: We conducted a single center review of pediatric heart transplant patients who underwent transfer of care to the adjacent adult heart transplant center. Patient mortality and associated variables were analyzed. Results: Forty‐eight patients were transferred at a mean age of 19 ± 0.9 years, with 3.9 ± 2.7 years of follow‐up time after transfer. There were 14 (29.2%) patient deaths at a median time of 1.3 years after transfer. On survival analysis, Black race ( p < 0.001), public insurance ( p = 0.04), single parent household ( p = 0.057), treated rejection in the final year before transfer ( p < 0.001), and shorter interval between transplant and transfer of care ( p = 0.003) were all associated in a univariate fashion with mortality. On multivariable analysis, recent rejection (HR 6.29, 95% CI 1.6–25.1) and time between transplant and transfer of care (HR 0.75, 95% CI 0.6–1) were associated with an increased and decreased risk, respectively, of mortality. Conclusions: Our results reveal the extent of mortality after transfer of care to an adult institution and suggest possible associations between mortality and the following risk factors: race, socioeconomic characteristics, older age at transplant, and recently treated rejection.
- 22 June 2023
- Published by Springer Nature
- p. 241-246
Potential Applicability of Cardiac Xenotransplantation in Pediatrics: Just Around the Corner
- 22 June 2023
- Published by Springer Nature
- p. 241-246
Potential Applicability of Cardiac Xenotransplantation in Pediatrics: Just Around the Corner
- 4 March 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1074-1081
Single-drug immunosuppression is associated with noninferior medium-term survival in pediatric heart transplant recipients
- 4 March 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1074-1081
Single-drug immunosuppression is associated with noninferior medium-term survival in pediatric heart transplant recipients
- 2 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14456
The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study
Background: Patients after Fontan palliation represent a growing pediatric population requiring heart transplant (HTx) and often have lymphopenia (L) and/or hypogammaglobinemia that may be exacerbated by protein‐losing enteropathy (PLE, P). The post‐HTx effects of this altered immune phenotype are not well studied.Methods: In this study of the Pediatric Heart Transplant Society Registry, 106 Fontan patients who underwent HTx between 2005 and 2018 were analyzed. The impact of lymphopenia and PLE on graft survival, infection, rejection, and malignancy was analyzed at 1 and 5 years post‐HTx.Results: The following combinations of lymphopenia and PLE were noted: +L+P, n = 37; +L−P, n = 23; −L+P, n = 10; and −L−P, n = 36. Graft survival between the groups was similar within the first year after transplant (+L+P: 86%, +L−P: 86%, −L+P: 87%, −L−P: 89%, p = .9). Freedom from first infection post‐HTx was greatest among −L−P patients compared to patients with either PLE, lymphopenia, or both; with a 22.1% infection incidence in the −L−P group and 41.4% in all others. These patients had a significantly lower infection rate in the first year after HTx (+L+P: 1.03, +L−P: 1, −L+P: 1.3, −L−P: 0.3 infections/year, p < .001) and were similar to a non‐single ventricle CHD control group (0.4 infections/year). Neither freedom from rejection nor freedom from malignancy 1 and 5 years post‐HTx, differed among the groups.Conclusions: Fontan patients with altered immunophenotype, with lymphopenia and/or PLE, are at increased risk of infection post‐HTx, although have similar early survival and freedom from rejection and malignancy. These data may encourage alternative immunosuppression strategies and enhanced monitoring for this growing subset of patients.
- 2 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14456
The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study
Background: Patients after Fontan palliation represent a growing pediatric population requiring heart transplant (HTx) and often have lymphopenia (L) and/or hypogammaglobinemia that may be exacerbated by protein‐losing enteropathy (PLE, P). The post‐HTx effects of this altered immune phenotype are not well studied.Methods: In this study of the Pediatric Heart Transplant Society Registry, 106 Fontan patients who underwent HTx between 2005 and 2018 were analyzed. The impact of lymphopenia and PLE on graft survival, infection, rejection, and malignancy was analyzed at 1 and 5 years post‐HTx.Results: The following combinations of lymphopenia and PLE were noted: +L+P, n = 37; +L−P, n = 23; −L+P, n = 10; and −L−P, n = 36. Graft survival between the groups was similar within the first year after transplant (+L+P: 86%, +L−P: 86%, −L+P: 87%, −L−P: 89%, p = .9). Freedom from first infection post‐HTx was greatest among −L−P patients compared to patients with either PLE, lymphopenia, or both; with a 22.1% infection incidence in the −L−P group and 41.4% in all others. These patients had a significantly lower infection rate in the first year after HTx (+L+P: 1.03, +L−P: 1, −L+P: 1.3, −L−P: 0.3 infections/year, p < .001) and were similar to a non‐single ventricle CHD control group (0.4 infections/year). Neither freedom from rejection nor freedom from malignancy 1 and 5 years post‐HTx, differed among the groups.Conclusions: Fontan patients with altered immunophenotype, with lymphopenia and/or PLE, are at increased risk of infection post‐HTx, although have similar early survival and freedom from rejection and malignancy. These data may encourage alternative immunosuppression strategies and enhanced monitoring for this growing subset of patients.
- 1 January 2023
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 14 (1) , 25-30
Association Between Venous Homografts and Allosensitization After Norwood Procedure
Background: Right ventricle (RV) to pulmonary artery (PA) shunts have become the shunt of choice at many centers for use during the Norwood procedure for single ventricle palliation. Some centers have begun to use cryopreserved femoral or saphenous venous homografts as an alternative to polytetrafluoroethylene (PTFE) for shunt construction. The immunogenicity of these homografts is unknown, and potential allosensitization could have significant implications on transplant candidacy. Methods: All patients undergoing Glenn procedure at our center between 2013 and 2020 were screened. Patients who initially underwent Norwood procedure with either PTFE or venous homograft RV-PA shunt and had available pre-Glenn serum were included in the study. The primary outcome of interest was panel reactive antibody (PRA) level at the time of Glenn surgery. Results: Thirty-six patients met inclusion criteria (N = 28 PTFE, N = 8 homograft). Patients in the homograft group had significantly higher median PRA levels at the time of Glenn surgery (0% [IQR 0-18] PTFE vs 94% [IQR 74-100] homograft, P = .003). There were no other differences between the two groups. Conclusions: Despite potential improvements in PA architecture, the use of venous homografts for RV-PA shunt construction at the time of Norwood procedure is associated with significantly elevated PRA level at the time of Glenn surgery. Centers should carefully consider the use of currently available venous homografts given the high percentage of these patients who may require future transplantation.
- 1 January 2023
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 14 (1) , 25-30
Association Between Venous Homografts and Allosensitization After Norwood Procedure
Background: Right ventricle (RV) to pulmonary artery (PA) shunts have become the shunt of choice at many centers for use during the Norwood procedure for single ventricle palliation. Some centers have begun to use cryopreserved femoral or saphenous venous homografts as an alternative to polytetrafluoroethylene (PTFE) for shunt construction. The immunogenicity of these homografts is unknown, and potential allosensitization could have significant implications on transplant candidacy. Methods: All patients undergoing Glenn procedure at our center between 2013 and 2020 were screened. Patients who initially underwent Norwood procedure with either PTFE or venous homograft RV-PA shunt and had available pre-Glenn serum were included in the study. The primary outcome of interest was panel reactive antibody (PRA) level at the time of Glenn surgery. Results: Thirty-six patients met inclusion criteria (N = 28 PTFE, N = 8 homograft). Patients in the homograft group had significantly higher median PRA levels at the time of Glenn surgery (0% [IQR 0-18] PTFE vs 94% [IQR 74-100] homograft, P = .003). There were no other differences between the two groups. Conclusions: Despite potential improvements in PA architecture, the use of venous homografts for RV-PA shunt construction at the time of Norwood procedure is associated with significantly elevated PRA level at the time of Glenn surgery. Centers should carefully consider the use of currently available venous homografts given the high percentage of these patients who may require future transplantation.
- 15 November 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (2) , e14435
Fontan‐associated liver disease after heart transplant
Background: Fontan associated liver disease (FALD) potentially impacts Fontan patients undergoing heart transplant. This multi‐center study sought to identify pre‐transplant risk factors and characterize any post‐transplant liver recovery in those patients undergoing heart‐alone transplant.Methods: Review of Fontan patients at 12 pediatric institutions who underwent heart transplant between 2001‐2019. Radiologists reviewed pre and post‐transplant liver imaging for fibrosis. Laboratory, pathology and endoscopy studies were reviewed.Results: 156 patients underwent transplant due to decreased ventricular function (49%), protein losing enteropathy (31%) or plastic bronchitis (10%); median age at transplant was 13.6 years (interquartile range IQR 7.8, 17.2) with a median of 9.3 years (IQR 3.2, 13.4) between the Fontan operation and transplant. Few patients had pre‐transplant endoscopy (18%), and liver biopsy (19%). There were 31 deaths (20%). The median time from transplant to death was 0.5 years (95% Confidence Interval CI 0.0, 3.6). The five‐year survival was 73% (95% CI 64%, 83%). Deaths were related to cardiac causes in 68% (21/31) and infection in 6 (19%). A pre‐transplant elevation in bilirubin was a predictor of death. Higher platelet levels were protective. Immediate post‐transplant elevations in creatinine, AST, ALT, and INR were predictive of death. Advanced liver fibrosis identified on ultrasound, computed tomography, or magnetic resonance imaging was not predictive of death. Liver imaging suggested some improvement in liver congestion post‐transplant.Conclusions: Elevated bilirubin, but not fibrosis on liver imaging, was associated with post‐heart transplant mortality in Fontan patients in this multicenter retrospective study. Additionally, heart transplant may alter the progression of FALD.
- 15 November 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (2) , e14435
Fontan‐associated liver disease after heart transplant
Background: Fontan associated liver disease (FALD) potentially impacts Fontan patients undergoing heart transplant. This multi‐center study sought to identify pre‐transplant risk factors and characterize any post‐transplant liver recovery in those patients undergoing heart‐alone transplant.Methods: Review of Fontan patients at 12 pediatric institutions who underwent heart transplant between 2001‐2019. Radiologists reviewed pre and post‐transplant liver imaging for fibrosis. Laboratory, pathology and endoscopy studies were reviewed.Results: 156 patients underwent transplant due to decreased ventricular function (49%), protein losing enteropathy (31%) or plastic bronchitis (10%); median age at transplant was 13.6 years (interquartile range IQR 7.8, 17.2) with a median of 9.3 years (IQR 3.2, 13.4) between the Fontan operation and transplant. Few patients had pre‐transplant endoscopy (18%), and liver biopsy (19%). There were 31 deaths (20%). The median time from transplant to death was 0.5 years (95% Confidence Interval CI 0.0, 3.6). The five‐year survival was 73% (95% CI 64%, 83%). Deaths were related to cardiac causes in 68% (21/31) and infection in 6 (19%). A pre‐transplant elevation in bilirubin was a predictor of death. Higher platelet levels were protective. Immediate post‐transplant elevations in creatinine, AST, ALT, and INR were predictive of death. Advanced liver fibrosis identified on ultrasound, computed tomography, or magnetic resonance imaging was not predictive of death. Liver imaging suggested some improvement in liver congestion post‐transplant.Conclusions: Elevated bilirubin, but not fibrosis on liver imaging, was associated with post‐heart transplant mortality in Fontan patients in this multicenter retrospective study. Additionally, heart transplant may alter the progression of FALD.
- 13 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1773-1780
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction
- 13 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1773-1780
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction